10 results on '"Buffardi, Salvatore"'
Search Results
2. The prognostic value of biological markers in paediatric Hodgkin lymphoma
3. Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study
4. Ileal inflammatory pseudotumor in adolescent male patient with prior Burkitt lymphoma: A challenging diagnosis
5. HL-032: Nivolumab and Brentuximab Vedotin (BV)–Based, Response-Adapted Treatment in Children, Adolescents, and Young Adults (CAYA) With Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Primary Analysis of the Standard-Risk Cohort of the Phase 2 CheckMate 744 Study
6. Response-Adapted Treatment with Nivolumab and Brentuximab Vedotin (BV) in Children, Adolescents and Young Adults (CAYA) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): CheckMate 744 Subgroup Analyses
7. Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma
8. Efficacy of Dasatinib to Treat Molecular Relapse in an Adolescent with Philadelphia-Positive Acute Lymphoblastic Leukemia
9. Brentuximab Vedotin in Combination with Bendamustine in Relapsed or Refractory Hodgkin Lymphoma: A Retrospective Analysis on 23 Paediatric Patients or Young Adults
10. Minimal Disseminated Disease Is An Independent Poor Prognosis Marker Among High Risk Burkitt's Lymphoma Patients .
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.